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Induction of cachexia in mice by a product isolated from
the urine of cachectic cancer patients
P Cariukl, MJ Loritel, PT Todorovl, WN Field', SJ Wigmore2 and MJ Tisdale'
'Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, UK; 2Department of Surgery, University of Edinburgh, Royal Infirmary,
Launston Place, Edinburgh EH3 9YW, UK
Summary Urine from cancer patients with weight loss showed the presence of an antigen of Mr 24 000 detected with a monoclonal antibody
formed by fusion of splenocytes from mice with cancer cachexia. The antigen was not present in the urine of normal subjects, patients with
weight loss from conditions other than cancer or from cancer patients who were weight stable or with low weight loss (1 kg month-1). The
antigen was present in the urine from subjects with carcinomas of the pancreas, breast, lung and ovary. The antigen was purified from urine
using a combination of affinity chromatography with the mouse monoclonal antibody and reversed-phase high-performance liquid
chromotography (HPLC). This procedure gave a 200 000-fold purification of the protein over that in the original urine extract and the material
isolated was homogeneous, as determined by silver staining of gels. The N-terminal amino acid sequence showed no homology with any of
the recognized cytokines. Administration of this material to mice caused a significant (P<0.005) reduction in body weight when compared with
a control group receiving material purified in the same way from the urine of a normal subject. Weight loss occurred without a reduction in food
and water intake and was prevented by prior administration of the mouse monoclonal antibody. Body composition analysis showed a
decrease in both fat and non-fat carcass mass without a change in water content. The effects on body composition were reversed in mice
treated with the monoclonal antibody. There was a decrease in protein synthesis and an increase in degradation in skeletal muscle. Protein
degradation was associated with an increased prostaglandin E2 (PGE2) release. Both protein degradation and PGE2 release were significantly
reduced in mice pretreated with the monoclonal antibody. These results show that the material of Mr 24 000 present in the urine of cachectic
cancer patients is capable of producing a syndrome of cachexia in mice.
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Progressive weight loss is a common feature of many types of
cancer and is particularly prominent in patients with carcinomas of
the pancreas and stomach (DeWys et al, 1980). The degree of
expression of cachexia varies, even among patients with identical
stage and tumour histology, and bears no simple correlation to
tumour burden, tumour cell type or anatomical site of involvement
(Costa, 1977). Although anorexia frequently accompanies
cachexia, there is some evidence to suggest that it may develop
after weight loss as a result of nausea associated with disease
progression (Warnold et al, 1978). In addition, studies with total
parenteral nutrition indicate that many patients either maintain
body weight or lose weight while receiving calories, which would
be predicted to result in weight gain (Heber et al, 1986). This
suggests that decreases in food intake alone may be insufficient to
account for cachexia and that cachexia-inducing factors may be
produced by some tumour types.
Most research effort has focused on the role of cytokines as
mediators of the process of cachexia, particularly tumour necrosis
factor alpha (TNF-a) and interleukin 6 (IL-6). Implantation into
mice of Chinese hamster ovary (CHO) cells transfected with the
gene for TNF-a produces a syndrome resembling cancer cachexia
with progressive wasting, anorexia and early death (Oliff et al,
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1987). However, most studies have failed to measure circulating
TNF-ax in cachectic cancer patients (Socher et al, 1988), despite
the requirement for high levels of TNF-a to induce cachexia in
experimental models. Even in some cancer patients in whom
elevated levels of TNF-a may be present, this does not seem to be
correlated with the presence of cachexia (Balkwill et al, 1987;
Saarinen et al, 1990). Although CHO cells transfected with the IL-
6 gene have been shown to produce a syndrome of cachexia in
nude mice (Black et al, 1991), cachexia is not observed in patients
with IL-6-producing tumours, at least during the early stage of
tumour growth (Ishibashi et al, 1993). In addition, serum levels of
IL-6 have been found to increase to similar levels in two clones
of colon 26 adenocarcinoma, although only one produced the
syndrome of cachexia when transplanted into syngenic mice (Soda
et al, 1994). These results suggest that other factors may contribute
to the development of cachexia.
We have recently described a proteoglycan of Mr 24 000,
detected by Western blotting using serum from mice bearing a
cachexia-inducing tumour (MAC16), that was present in the urine
of patients with cancer cachexia, but absent from the urine of
normal subjects (McDevitt et al, 1995; Todorov et al, 1996a). The
material was not detected using serum from mice bearing a related
tumour (MAC 13) that does not induce cachexia. Intravenous
administration of the proteoglycan purified from the MAC16
tumour into non-tumour-bearing mice produced a state of cachexia
with rapid loss of body mass (Todorov et al, 1996a). This study
documents the isolation of a similar material ofMr 24 000 from the
urine of cachectic cancer patients by affinity chromatography
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Table 1 Clinical characterstics of cancer patients
Patient Sex Age Diagnosis Weight loss Western
(kg month-1) blot
Pancreatic cancer stage IV
Pancreatic cancer stage III
Pancreatic cancer stage IlIl
Pancreatic cancer
Pancreatic cancer
Pancreatic cancer
Pancreatic cancer
Pancreatic cancer
Pancreatic cancer
Pancreatic cancer + megace
Cholangiocarcinoma stage IV
Pancreatic cancer stage IlIl
Pancreatic cancer stage IV
Pancreatic cancer stage III/IV
Pancreatic cancer stage IlIl
Pancreatic cancer stage IlIl
Pancreatic cancer stage 11
Pancreatic cancer stage IV
Pancreatic cancer stage IV
Pancreatic cancer stage IV
Pancreatic cancer stage 11
Pancreatic cancer stage IV
Pancreatic cancer stage III
Pancreatic cancer stage III
Carcinoma of breast
Carcinoma of ovary
Pancreatic cancer
Carcinoma of breast
Carcinoma of breast
Carcinoma of lung
Carcinoma of lung
Pancreatic cancer
Pancreatic cancer stage IV
Pancreatic cancer
Pancreatic cancer
Pancreatic cancer stage 11
Pancreatic cancer stage 11
Pancreatic cancer
Pancreatic cancer stage IV
Pancreatic cancer
Pancreatic cancer
Pancreatic cancer
Colon adenocarcinoma
Rectal adenocarcinoma
Rectal adenocarcinoma
Cholangiocarcinoma
Hepatocellular carcinoma
2.5
3.0
0
2.9
1.5
0.7
1.3
0
2.7
0.13
1.3
1.8
2.0
2.3
2.5
1.0
1.0
1.5
2.5
5.0
4.6
5.0
5.0
10.0
1.7
3.8
3.6
0.4
0.3
0
3.0
2.1
2.8
1.5
2.0
1.0
1.0
2.7
2.5
1.6
1.5
4.0
1.7
0
4.3
4.2
Unknown
+
+
+
+
+
+
+
pancreas, two lung cancers, two rectal cancers, three breast
cancers, one colon adenocarcinoma, one ovarian cancer, one hepa-
tocellular carcinoma and two cholangiocarcinomas. The cancer
patients showed varying degrees of weight loss and the normal
subjects were all weight stable. The urine was stored frozen
(-20°C), without preservatives, before assay in sterile containers.
For the patients with pancreatic carcinoma a minimum of 4 weeks
had elapsed between surgical bypass or endoscopic stenting and
study. No patient had evidence of active infection at the time of
study or was receiving chemotherapy or radiotherapy. Patients
were asked to recall their pre-illness stable weight and duration of
weight loss, and this was validated where possible from patient
records. Patients were weighed on spring-balance scales (Seca,
Germany) without shoes and wearing light clothing. Actual weight
loss, weight loss as a percentage of pre-illness stable weight and
rate of weight loss were then calculated. Patients with weight loss
from causes other than cancer were not weighed, but were
observed clinically to be losing weight. Patients with multiple
injuries lose up to 5 kg week-'.
Western blotting
Urine (20 ml) was treated with ammonium sulphate (80%, w/v)
and stirred overnight at 4°C. The precipitated protein was recov-
ered by centrifugation at 3 000 g for 30 min, dialysed against water
through an Amicon filtration cell containing a membrane filter
with a molecular weight cut-off of 10000 and concentrated.
Samples (5 jig) were loaded on sodium dodecylsulphate polyacryl-
amide gels, prepared according to the method of Laemmli (1970)
and consisted of a 5% stacking gel and a 15% resolving gel.
For immunoblotting, gels were transferred to nitrocellulose
membranes (Hoefer Scientific Instruments, San Francisco, CA,
USA); which had been blocked with 5% Marvel in 0.15% Tween-
20 in phosphate-buffered saline (PBS) at 4°C overnight. The
membranes were washed once for 15 min in 0.5% Tween-20 in
PBS, followed by two more washes for 5 min in Tween/PBS. The
membranes were further incubated for 1 h at room temperature in
Tween/PBS containing 1.5% Marvel and 10 jig ml-' of the mono-
clonal antibody, prepared as described (Todorov et al, 1996b), and
which had been biotinylated using the ECL protein biotinylation
module (Amersham, UK). After being washed three times as
above, the filters were incubated for 1 h at room temperature with
streptavidin-horseradish peroxidase conjugate (Amersham) at a 1-
to 1500-fold dilution followed by three 15 min washes with 0.1%
Tween in PBS. Bands were detected with an emission chemilumi-
nescence (ECL) system (Amersham).
using a monoclonal antibody produced by fusion of splenocytes
from mice bearing the MAC16 tumour with BALB/C myeloma
cells, and screened for antibodies to the Mr 24 000 material
(Todorov et al, 1996b). The role of this material in cancer cachexia
has now been evaluated.
MATERIALS AND METHODS
Subjects
Twenty-four-hour urine collections were made from normal
subjects (12), in-hospital patients who were losing weight through
causes other than cancer (24) and cancer patients (47). The clinical
characteristics of the subjects are shown in Table 1 and include 35
patients with unresectable carcinoma arising in the head of the
Purification of immunoreactive material from cancer
patient urine
Urine samples were thawed and particulate material removed by
centrifugation at 16 000 g for 30 min at room temperature. The
volume was reduced to about 500 ml by ultrafiltration using an
Amicon filtration cell. Solid ammonium sulphate was added over a
6-h period with constant stirring at 4'C until a concentration of
80% (w/v) was achieved, and stirred overnight. The precipitated
protein was recovered by centrifugation at 3000 g for 30 min and
salt was removed by dialysis against PBS (three times), using an
Amicon filtration cell with a membrane filter having a molecular
weight cut-off of 10 000 to a final volume of 20 ml. The solution
was applied to an affinity column containing monoclonal antibody
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Figure 1 (A) Immunoblot of unfractionated urine using the mouse
monoclonal antibody. Lane 1 represents urine obtained from cancer patient
number 33 (Table 1A), whereas lanes 2-4 represent urine obtained from
normal subjects numbers 6, 7 and 9 respectively (Table 1 B). (B) Western blot
of urine obtained from cancer patients numbers 18, 8 and 37 (Table 1A)
(lanes 1-3) and weight-losing non-cancer patients numbers 3, 2 and 1 (Table
1 C) (lanes 4-6 respectively). (C) Western blot of urine obtained from cancer
patients numbers 33 and 9 (Table 1 A) (lanes 1 and 2 respectively) and non-
cancer patients with weight loss numbers 8 and 10 (Table 1 C) (lanes 3 and 4
respectively)
coupled to Affi Gel Hz (Biorad, Hemel Hempstead, UK) and
circulated for 19 h. The column was then washed with 10 mm Tris-
HCl, pH 8.0, for 4 h and the retained proteins were eluted with
100 mm glycine-HCl, pH 2.5. The immunoreactive fractions,
determined by an ELISA plate assay using the mouse monoclonal
antibody (Todorov et al, 1996b), were pooled and the volume was
reduced by ultrafiltration against water in an Amicon filtration
cell. Portions (50 gl) were fractionated using reversed-phase
hydrophobic chromatography with a Brownlee Aquapore RP-300
C8 column (Applied Biosystems), size 100 x 2.1 mm. The flow
rate was 0.2 ml min-' with solvent system A [HPLC grade water
(Fisons, Loughborough, UK) plus 0.06% trifluoroacetate (TFA)]
or B [acetonitrile 190, Romil Chemicals, Loughborough, UK) plus
0.04% TFA]. The gradient was 2-65% B in A over a 30 min period
followed by 65-100% B in A over 10 min and 100% B for 10 min.
Absorbance was monitored at 214 nm.
Tyrosine-release assay
Mice were injected i.v. with the affinity-purified material (150 pl
x 4) and after 24 h the soleus muscles were ligated by the tendons,
dissected out intact and placed in ice-cold isotonic saline. They
were then quickly ligated to stainless-steel supports under slight
tension, which resembled that observed at resting length in vivo,
and incubated for 2 h in Krebs-Henseleit buffer containing 6 mm
D-glucose, 1.2 mg ml-' bovine serum albumin and 130 tg ml-'
cycloheximide with continuous gassing. At the end of the incuba-
tion, the buffer was removed, deproteinized with ice-cold 30%
trichloroacetic acid (0.2 ml), centrifuged at 2800 g for 10 min and
the supernatant was used for the measurement of tyrosine by a
fluorimetric method (Waalkes and Udenfriend, 1957) at 570 nm on
a Perkin-Elmer LS-5 luminescence spectrometer.
Prostaglandin E2 determination
A portion (100 ,l) of the soleus muscle incubation medium was
mixed with [5,6,8,11,12,14,15-3H(N)]-prostaglandin E2 (0.1 ,Ci; sp.
act. 154 Ci mmol-') (Amersham) and PGE2 rabbit antiserum (Sigma
Chemical, Poole, Dorset UK) (for the particular batch a 1:20 dilu-
tion was used to give 40% binding of [3H]PGE2 in 100 gl) in
Eppendorf tubes, vortexed and incubated for 1 h at 37°C. Samples
were then kept at 4°C for 5 min and a mixture of ice-cold dextran
charcoal (500 pl) was added and allowed to stand for 15 min at 4'C.
Bound and unbound material were separated by centrifugation
(2000g for 10 min at 4°C) and the concentration of PGE2 was deter-
mined from standard curves prepared on the same day.
Determination of protein synthesis in organs
Mice were administered 0.25 ml of physiological saline containing
0.4 mM L-[4-3H]phenylalanine (15.6 ,uCi) by i.p. injection together
with i.v. injections of affinity-purified urine. Twenty-four hours
after isotope injection, the animals were killed by cervical disloca-
tion and the organs were removed and weighed and homogenized
in 2% perchloric acid (4 ml). The homogenate was centrifuged at
2800 g for 15 min and the supematant was converted to a pH close
to 6 by the addition of 1-5 ml of saturated tripotassium citrate. The
insoluble potassium perchlorate was removed by centrifugation at
2800 g for 15 min and 1 ml of the supernatant was diluted (1:1)
and added to 10 ml of Optiphase Hi-safe 3 scintillation fluid (FSA
Laboratory Supplies, Loughborough, UK) for the measurement of
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Table 2 Characteristics of normal subjects
Number Sex Age Western blot
1 M 50
2 F 28 -
3 M 25 -
4 M 46 -
5 F 23 -
6 F 24 -
7 M 50 -
8 M 26 -
9 M 32 -
10 M 24 -
11 F 25 -
12 F 39 -
Table 3 Clinical characteristics of weight-losing non-cancer patients
Patient Sex Age Diagnosis Western blot
1 M 43 Liver resection -
2 M 30 Ulcer/surgery -
3 M 63 Sepsis
4 M 25 Multiple injuries -
5 F 38 Burns
6 F 80 Burns
7 M 63 Multiple injuries -
8 M 23 Multiple injures -
9 M 26 Multiple injuries -
10 M 52 Multiple injuries -
11 M 49 Severe sepsis -
12 M 32 Severe sepsis -
13 F 21 Severe sepsis -
14 M 23 Acute pancreatitis -
15 M 28 Coeliac disease -
16 F 37 Gl surgery
17 M 35 Surgery
18 M 69 Multiple injuries -
19 M 70 Multiple injuries -
20 F 23 Multiple injuries -
21 M 44 Multiple injuries -
22 F 16 Multiple injuries -
23 M - Sleeping sickness -
24 F - Sleeping sickness -
the intracellular free pool of L-[4-3H]phenylalanine by liquid scin-
tillation spectrometry. The precipitate from the original centrifuga-
tion was washed three times with 2% perchloric acid (4 ml) and
hydrolysed in 6 M hydrochloric acid (5 ml) at 110°C in sealed glass
tubes for 24 h. The hydrolysates were evaporated to dryness and
the residue was dissolved in water (10 ml). A 1 ml sample of the
solution was counted for [3H]phenylalanine radioactivity to give
the protein-bound radioactivity. The rate of protein synthesis was
calculated by dividing the amount of protein-bound radioactivity
by the amount of acid-soluble radioactivity.
Plasma metabolite levels
Glucose, triglyceride and 3-hydroxybutyrate were measured by
quantitative enzymatic determination (Sigma Diagnostics). Fatty
acids were determined by a kit purchased from Wako Chemicals,
Neuss, Germany.
Table 4 Purification of immunoreactive material from patient urine
Stage Protein Recovery Purification
(mg) (%) fold
80% Ammonium sulphate 99.4 - -
Affinity chromatography 0.6 0.12 168
Reversed phase HPLC 0.0005 5 x 104 198 800
RESULTS
A substance of apparent Mr 24 000 has previously been detected in
the urine of patients with cancer cachexia using serum from mice
transplanted with the MAC 16 adenocarcinoma (McDevitt et al,
1995). Hybridomas have now been produced using splenocytes
from mice transplanted with the MAC16 tumour and cloned to
produce antibodies recognizing the mouse Mr 24 000 material
(Todorov et al, 1996b). Western blots of an 80% ammonium
sulphate precipitate of whole urine, using the mouse monoclonal
antibody, showed evidence for similar immunoreactive material of
Mr 24 000 in the urines of cancer patients with weight loss (Figure
IA). Such immunoreactive material was not present in the urine of
12 normal subjects tested (Table 2 and Figure IA). In addition,
patients losing weight through conditions other than cancer -
major surgery (four), sepsis (four), multiple injuries (nine), burns
(two), acute pancreatitis (one), coeliac disease (one) and sleeping
sickness (two) - showed no evidence of a similar immunoreactive
band of Mr 24 000 on Western blots of urine extracts (Figure lB
and C and Table 3). The ability to detect the band of Mr 24 000 on
Western blots of cancer patients was dependent more on the rate of
weight loss than on tumour type (Table 1 and Figure 1B). Thus,
patients with pancreatic, lung, colon, breast, rectal, liver, ovarian
and cholangiocarcinoma, in whom the rate of weight loss was
greater than or equal to about 1.0 kg month-' showed evidence of
excretion of the Mr 24 000 material. Patients who were weight
stable or in whom the rate of weight loss was equal to or less than
1.0 kg month-' showed no evidence of such excretion.
To gain more information on the nature and function of the
Mr 24 000 substance, urine from cachectic cancer patients that was
positive by Western blotting was purified by a combination of
affinity chromatography and reversed-phase HPLC (Table 4). The
procedure for affinity chromatography involved an initial ammo-
nium sulphate precipitation of urine, which was then applied to a
column of Affi-gel Hz, containing bound mouse monoclonal anti-
body. Bound material was eluted with glycine-HCl, pH 2.5, and
the immonoreactive fractions, determined by Western blotting
(Figure 2A), represented only 0.12% of the protein present in the
ammonium sulphate precipitate, giving a 168-fold purification.
Further fractionation of immunoreactive material was achieved
using reversed-phase hydrophobic chromatography on a C8
column, with an acetonitrile and water gradient. The immunoreac-
tive fraction eluted at 56% acetonitrile as determined by Western
blotting (Figure 2B) and was present as a single component as
determined by silver staining of gels (Figure 2C). The protein
recovery at this step was 5 x 104%, representing almost a
200 000-fold purification from the ammonium sulphate precipitate
(Table 4). The material stained heavily for carbohydrate as deter-
mined by the digoxigenin glycan detection kit (Amersham). The
N-terminal amino acid sequence of this material is shown in Table
5 and has no homology with any of the recognized cytokines, but
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Table 5 N-terminal amino acid sequence of immunoreactive material
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Figure 2 (A) Western blot of fractions of human urine from patient 19 (Table
1 A) isolated by affinity chromatography. (B) Western blot of fractions eluted
from the reverse phase C8 column of affinity purified urine from patient 23
identified by absorption at 214 nm. Lanes 1-5, decreasing concentrations of
acetonitrile: lane 1, 81%; lane 2, 76%; lane 3, 65%; lane 4, 56%; lane 5,
52%. (C) Silver stain of SDS gel of material eluting at 56% acetonitrile (lane
1) and affinity-purified material (lane 2)
is homologous to material of Mr 24 000 from the MAC16 tumour
(Todorov et al, 1996a,b).
To investigate the biological effects of the immunoreactive
material from cancer patients' urine, mice were treated by i.v.
injection and the effect on body weight and food and water intake
was monitored over a 24-h period. The results depicted in Figure 3
show a significant (P < 0.005) reduction in the body weight of
0.5 1
0
0)
-1
-1.5
-2
0 5 10 15 20 25
Time (h)
Figure 3 Effect of purified urine extract on body weight of female NMRI mice
(average weight 19 g). Material purified from urine of patient 4 (150 ,ul; 1 ,ug
protein) were injected into the tail vein of five female NMRI mice at 1.5-h
intervals (10.30, 12.00, 13.30 and 15.00 h) and body weight was monitored
over a 24-h period (*). Control animals (A) received material purified from
the urine of normal subjects, whereas the third group received monoclonal
antibody (two injections of 0.4 mg of protein in 250 tli of PBS by i.p. injection)
24 h before the first injection of the purified cachectic urine extract (U). The
results are means ± s.e.m. for five mice per group and the experiment was
repeated five times. At 24 h the body weight of mice receiving the cachectic
urine was significantly different (P < 0.0005) from that of the control group as
determined using an unpaired Student's t-test. Body weight in the mice
pretreated with the monoclonal antibody was significantly different (P < 0.05)
from that of the untreated group. Both food and water intake were monitored
during the course of the experiment
mice receiving material purified from the urine of a cachectic
cancer patient when compared with a control group receiving
material purified in the same way from a normal subject. Weight
loss occurred without an effect on food (3.3 g per mouse) and
water (3.2 ml per mouse) intake compared with controls (3.5 g per
mouse and 3.5 ml per mouse respectively). Pretreatment with the
mouse monoclonal antibody completely reversed the decrease in
body weight, showing the specificity of the human immuno-
reactive material (Figure 3). Analysis of individual body organs
showed a significant decrease in soleus muscle (from 7± 0.2 mg to
5 ± 0.4 mg; P < 0.025) and kidney weight (from 250 ± 2 mg to
220 ± 1 mg; P < 0.05). Body composition analysis showed a small
decrease in total body fat and a significant decrease in total carcass
non-fat dry weight without a change in water composition (Table
6). The effects on fat and non-fat carcass mass were reversed in
animals pretreated with the monoclonal antibody. Analysis of
British Journal of Cancer (1997) 76(5), 606-613
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Table 6 Effect of purified urine extracts on body composition and plasma metabolite levels in female NMRI mice 24 h after treatmenta
Group Dry weight Fat Water Glucose Fatty acid Triglyceride 3-Hydroxybutyrate
(g) (g) (%) (mg 100 ml-,) (mequiv.) (mg 100 ml-') (mg 100 ml-')
Control 5.70 + 0.2 1.21 + 0.16 70.6 + 0.4 250 ± 8 0.44 ± 0.04 104 + 11 1.5 + 0.2
Cachectic 4.99 + 0.16b 1.03 + 0.17 69.8 + 0.9 221 + 8c 0.57 + 0.06 59 + 10c 0.6 + 0.4c
Cachectic + Ab 5.47 + 0.3 1.27 + 0.3 69.6 + 0.4 225 + 15 0.60 + 0.06 106 + 3 1.4 + 0.3
aAll values are given as mean + for five animals per group. Body composition analysis was performed as described (Beck and Tisdale, 1987); bp < 0.03 from
control group; cP < 0.05 from control group.
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Figure 4 (A) Protein synthesis (g3) and degradation (-) in mouse
gastrocnemius muscle 24 h after the administration of either purified normal
human urine extract (control) or extract from the urine of a cachectic cancer
patient (treated). Protein degradation was measured by the release of [4-3H]
phenylalanine as previously described (Smith and Tisdale, 1993a). (B)
Protein synthesis rates in heart (C), liver (P2), spleen (E) and kidney (-)
24 h after administration of the purified cachectic urine extract. Control mice
received material purified from the urine of normal subjects. Differences from
control group are indicated as ap < 0.05 and bp < 0.01 using Student's t-test
Soleus
Figure 5 Induction of tyrosine (A) and PGE2 (B) release from soleus muscle
24 h after administration of the purified cachectic urine extract alone (-) or
after prior administration of the mouse monoclonal antibody (E). Control mice
(E3) received material purified from the urine of normal subjects. Differences
from the control group are indicated as bp < 0.01 and from the group treated
with the cachectic urine extract ap < 0.05 and cP < 0.0005 by Student's t-test
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plasma metabolite levels (Table 6) showed a significant decrease
in blood glucose, 3-hydroxybutyrate and triglyceride levels and an
increase in non-esterified fatty acids after treatment with the
human Mr 24 000 proteoglycan. The effects on 3-hydroxybutyrate
and triglyceride levels were reversed by the monoclonal antibody.
The effect on protein synthesis in the individual organs is shown
in Figure 4. Treatment with the cachectic urine extract caused a
significant decrease in protein synthesis in gastrocnemius muscle
and an increase in protein degradation, as measured by the release
of [3H]phenylalanine (Figure 4A). Of the other organs, only heart
showed a significant decrease in protein synthesis (Figure 4B).
Protein degradation in soleus muscle was also significantly
increased as determined by tyrosine release (Figure 5A). The
increased protein degradation was correlated with an increased
prostaglandin E2 (PGE2) release (Figure SB). Both protein degra-
dation and PGE2 release in soleus muscle were significantly inhib-
ited in mice pretreated with the monoclonal antibody. These results
suggest that the material of Mr 24 000 present in the urine of
cachectic cancer patients may be responsible for the weight loss by
producing an increased protein degradation in skeletal muscle.
DISCUSSION
The first suggestion that cancer cachexia may be mediated by a
tumour product came from studies of Krebs-2 carcinoma cells in
mice, which showed that weight loss and, in particular, fat depletion
could be induced with non-viable preparations of the tumour (Costa
and Holland, 1966). Further evidence for a humoral mediation came
from two sources. In a parabiotic pair of rats, one of which bore a
cachexia-inducing sarcoma, the parabiotic tumour-free mouse also
developed cachexia, despite the absence of metastasis (Norton et al,
1985). In addition, serum from lymphoma-bearing mice, when
injected into normal mice, produced an immediate fat mobilization
that was not affected by feeding (Kitada et al, 1980). Our search for
a cachexia-inducing substance has been facilitated by the use of a
murine model system, the MAC 16 colon adenocarcinoma. Animals
bearing this tumour have elevated plasma levels of both lipolytic
and proteolytic factors, which may be responsible for the cachexia
(Beck and Tisdale, 1987). During the purification of a lipid-mobi-
lizing factor from this tumour, it was observed that some animals
with a delayed weight loss contained in their serum antibodies that
recognized a component of Mr 24 000 on Western blots (McDevitt
et al, 1995). This material co-purified with the lipid-mobilizing
factor. Recently, we have described the production of a monoclonal
antibody to this mouse material by fusion of splenocytes from mice
transplanted with the MAC 16 tumour with myeloma cells (Todorov
et al, 1996b). Material isolated from the MAC 16 tumour by affinity
chromatography also had Mr 24 000 and was capable of inducing
protein degradation in isolated gastrocnemious muscle and of
producing loss of body weight in vivo (Todorov et al, 1996a).
The mouse monoclonal antibody was capable of recognizing a
similar immunoreactive band of M 24 000 in the urine of cancer
patients with active weight loss. Such material was not detected in
the urine of normal subjects or cancer patients who were weight
stable or who had minimal weight loss. In addition, patients losing
weight through conditions other than cancer, such as major
surgery, sepsis, multiple injuries, burns, acute pancreatitis, coeliac
disease or sleeping sickness, had no evidence of the presence of
the immunoreactive material of Mr 24 000 in the urine. This
suggests that this material is specific to cancer cachexia and that
cachexia in other conditions is mediated by other factors. Weight
loss in sleeping sickness caused by trypanosome infection has
been attributed to TNF-ax (Beutler et al, 1985), whereas severe
weight loss associated with thermal injury has been attributed
to a combination of hypermetabolism, possibly due to elevated
catecholamines, and inadequate caloric intake (Gump and Kinney,
1971). Although the majority of the cancer patients we studied had
pancreatic carcinoma, the presence of immunoreactive material of
Mr 24 000 was not confined to this tumour type. A previous study
(Belezario et al, 1991) has shown serum from cancer patients with
weight loss to contain a material capable of inducing proteolysis in
skeletal muscle. Such material was not found in healthy subjects.
The nature of this material is not known. Another study reported a
substance of Mr 5000 in urine from cachectic cancer patients and
which was capable of causing lipid mobilization (Kitada et al,
1981). However, this is the first report of a substance of Mr 24000
in the urine of cachectic cancer patients with significant biological
activity.
Using the mouse monoclonal antibody, we have isolated, puri-
fied and partially sequenced the substance of Mr 24 000. Initial
studies show that it is either a glycoprotein or a proteoglycan and
that the sequence is homologous to a substance isolated from the
MAC 16 tumour (Todorov et al, 1996a). This suggests that the two
substances are identical. Intravenous injection of this substance in
mice causes a state of cachexia similar to that observed after
administration of the murine material (Todorov et al, 1996a) in
mice bearing the MAC16 tumour in that (a) weight loss occurs
without a reduction in food and water intake (Beck and Tisdale,
1987) and thus is not due to toxicity of the material, (b) weight loss
can be attenuated by prior administration of the monoclonal anti-
body, (c) there is marked hypoglycaemia (McDevitt and Tisdale,
1992) and (d) there is a decreased level of plasma triglycerides; in
the last respect the effect is unlike that of TNF-a, which causes an
increase (Mahony et al, 1988). This observation, together with the
finding of decreased plasma levels of 3-hydroxybutyrate, suggests
that energy expenditure may be increased. In mice bearing the
-MAC16 tumour, there is a gradual increase in rates of oxygen
consumption and carbon dioxide production with increasing
weight loss and an increase in energy expenditure leading to a
negative energy balance (Plumb et al, 1991). In this respect, the
MAC16 tumour is similar to some human tumours in which the
energy intake is not sufficient to meet the demands of an increased
energy expenditure (Hyltander et al, 1991).
Administration of the human immunoreactive material of
Mr 24 000 produces a depression in protein synthesis and an
increased protein degradation in skeletal muscle, as measured by
tyrosine release. Tyrosine is not metabolized in skeletal muscle and
represents a suitable indicator of protein balance. We have previ-
ously reported that cachectic mice bearing the MAC 16 tumour also
show reduced protein synthesis and increased protein degradation
in skeletal muscle and, moreover, that this effect can be mimicked
by serum from cachectic animals (Smith and Tisdale, 1993a). In
cancer patients, depletion of lean body mass has been attributed to
depressed protein synthesis (Rennie et al, 1983; Emery et al, 1984),
increased protein degradation (Levin et al, 1983) or generally
increased whole-body protein turnover (Kien and Camitta, 1983;
O'Keefe et al, 1990). The increased tyrosine release in isolated
soleus muscle from mice treated with the human immunoreactive
material has been correlated with an increased PGE2 release.
Abrogation of weight loss by the mouse monoclonal antibody was
associated with both reduced tyrosine release and reduced PGE2
production by soleus muscle. Previous studies (Smith and Tisdale,
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1993b) have also found increased PGE2 production in isolated
gastrocnemius muscle when incubated with serum from cachectic
mice. Inhibition of the rise in PGE2 also inhibited muscle protein
degradation. Other studies have also implicated PGE2 as a medi-
ator of muscle protein degradation (Rodeman and Goldberg, 1982;
Strelkov et al, 1989), although other factors may also be involved.
The mechanism by which the material of Mr 24 000 from cancer
patient urine induces PGE2 release or inhibits protein synthesis in
skeletal muscle is not known.
These results show that urine from patients with cancer
cachexia contains an immunoreactive substance that is capable of
producing in mice a syndrome resembling that of cancer cachexia.
Preliminary structural studies suggest that this material has a novel
structure that appears to be identical to that isolated from a
cachexia-inducing murine tumour and is distinct from that of the
recognized cytokines. Further structural studies are required to
characterize this material
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